Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + ipilimumab (Icahn School of Medicine at Mount Sinai)
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
Nivolumab + ipilimumab is a combination immunotherapy regimen being investigated by the Icahn School of Medicine at Mount Sinai for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This protocol, often referred to as 'immunotransplant,' combines dual checkpoint inhibition with adoptive T-cell transfer (ATCT). Nivolumab, a human IgG4 monoclonal antibody, targets the programmed death-1 (PD-1) receptor, while ipilimumab, a human IgG1 monoclonal antibody, targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). By blocking these inhibitory pathways, the combination aims to enhance the anti-tumor activity of both endogenous and adoptively transferred T cells following lymphodepleting chemotherapy. This approach is specifically targeted at DLBCL patients who are ineligible for standard autologous stem cell transplant due to chemotherapy insensitivity or inability to tolerate high-dose regimens.
- Brand names
- Opdivo + Yervoy
- Other names
- Nivolumab/Ipilimumab-Primed ImmunotransplantDual Checkpoint Blocking Antibody therapy
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on nivolumab + ipilimumab (Icahn School of Medicine at Mount Sinai).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + ipilimumab (Icahn School of Medicine at Mount Sinai).